Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Rennes – page 12

868 clinical trials in Rennes, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Rennes at a glance
868
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

868 trials in Rennes

Open in trial search

Head and neck cancer

Recruiting

Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Johnson & Johnson Enterprise Innovation Inc.

Postoperative care

Recruiting

Study on the Effect of Continuous Intravenous Lidocaine and Sodium Chloride on Comfort in Postoperative Critical Care Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Renal transplant

Recruiting

Study of Belatacept versus Tacrolimus in Kidney Transplant Recipients with Subclinical Antibody Mediated Rejection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belatacept
  • Sponsor:Centre Hospitalier Universitaire Rouen

Epileptic encephalopathy

Recruiting

Study on the Safety and Effectiveness of Bexicaserin for Seizures in Children and Adults with Developmental and Epileptic Encephalopathy

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.

Non-small cell lung cancer

Recruiting

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Multiple sclerosis

Recruiting

Study of [18F]-DPA-714 PET imaging to assess neuroinflammation in multiple sclerosis patients compared to healthy controls

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
  • Sponsor:Assistance Publique Hopitaux De Paris

Crohn's disease

Recruiting

Study on Fecal Microbiota Transplantation for Crohn's Disease Patients in Remission After Stopping Anti-TNF Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Placebo
  • Sponsor:Assistance Publique Hopitaux De Paris

Urethral valves

Recruiting

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Peripheral T-cell lymphoma unspecified+1

Recruiting

Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:LYSARC

Heart failure with reduced ejection fraction

Recruiting

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Omecamtiv mecarbil
  • Sponsor:Cytokinetics Inc.

Premature ejaculation

Recruiting

Study on the Effectiveness of BP1.4979 for Adult Men with Premature Ejaculation

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
  • Sponsor:Bioprojet Pharma

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Rennes

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancers, breast cancer, and hematologic malignancies. Studies are evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Advanced squamous cell carcinoma treatments
  • Triple-negative breast cancer interventions
  • Acute myeloid leukemia therapies

Multiple research centers are investigating breakthrough treatments for various stages of cancer progression.

02 Neurological Disorders

Comprehensive research into multiple sclerosis and movement disorders, utilizing advanced imaging techniques and innovative therapeutic approaches.

  • MS treatment optimization
  • Essential tremor management
  • Neuroinflammation imaging

Studies are focused on improving patient outcomes through targeted interventions and precision medicine approaches.

03 Critical Care Medicine

Investigating new approaches in postoperative care and immunotherapy for critical care patients, with emphasis on patient comfort and infection prevention.

  • Pain management protocols
  • Immune system modulation
  • Post-surgical care optimization

Research aims to enhance recovery outcomes and reduce complications in intensive care settings.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.